The Impact of COVID-19
on Clinical Research

 

CLICK TO LEARN MORE

What is the

Heart Failure Collaboratory (HFC)?

Efficiency of clinical trials and evidence generation in heart failure and foster development of therapies by creating a collaborative environment in which FDA, government agencies including NIH and CMS, and the heart failure community can interact to optimize innovation and advancement of new therapeutic products. HFC has established five working groups to tackle individual issues in clinical trials and fostering the development of effective heart failure therapies.


The Heart Failure Collaboratory is a public-private partnership with the FDA and the consortium to help foster the development of new products for heart failure.

Recent Publications

Access our latest publications, downloads and meeting notes.
Promoting Diversity in Clinical Trial Leadership: A Call to Action
As a community of investigators, we have struggled to improve the recruitment of representative populations into heart failure (HF) trials.
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
The purpose of this study was to evaluate in-hospital outcomes among patients with a history of heart failure (HF) hospitalized with coronavirus disease-2019 (COVID-19).
Approaches to the Treatment of Heart Failure in an Era of Multiple Therapies - Statement From the HF Collaboratory
The treatment of heart failure with reduced ejection fraction (HFrEF) has changed considerably over time, particularly with the sequential development of therapies aimed at antagonism of maladaptive biologic pathways. In an effort to provide a decision-making framework in the current era of expanding therapeutic options in HFrEF, the Heart Failure Collaboratory convened a multi-stakeholder group, including patients, clinicians, clinical investigators, the U.S. Food and Drug Administration, industry, and payers who met at the U.S. Food and Drug Administration campus on March 6, 2020. This paper summarizes the discussions and expert consensus recommendations.